

PubMed

Format: Abstract

Full text links

CNS Oncol. 2017 Jan;6(1):11-18. doi: 10.2217/cns-2016-0018. Epub 2016 Dec 5.



## First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.

O'Connell D<sup>1</sup>, Shen V<sup>1</sup>, Loudon W<sup>1</sup>, Bota DA<sup>1</sup>.

### Author information

### Abstract

We report the first case of a pediatric patient with glioblastoma (GBM; WHO grade IV astrocytoma) successfully treated with tumor treating fields (TTF). The patient was diagnosed with GBM when 13 years of age and progressed through surgical resection, radiotherapy and chemotherapy. Discrete tumor growth visualized on MRI with stable neurological examination was monitored for 6 months with subsequent stable disease observed radiographically and clinically for 7 months while adherent to Optune<sup>®</sup> (TTF). TTF thereby played a role in forestalling recurrent GBM growth in this young woman for 7 months without significant adverse effects. We propose that TTF therapy is a potential valuable treatment in this small, but sick, patient population.

**KEYWORDS:** CNS neoplasm; astrocytoma; bevacizumab; cisplatin; glioblastoma; glioma; pediatric; recurrence; temozolomide; tumor treating fields

PMID: 27918194 DOI: [10.2217/cns-2016-0018](https://doi.org/10.2217/cns-2016-0018)

[PubMed - in process]



LinkOut - more resources

PubMed Commons

[PubMed Commons home](#)

0 comments

[How to join PubMed Commons](#)